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DISSERTATION ABSTRACT 
 
Leslie Adrianne Coonrod 
 
Doctor of Philosophy 
 
Department of Biology 
 
June 2012 
 
Title: Targeting Myotonic Dystrophy with Small Molecules 
 
Myotonic dystrophy (DM) is one of the most common forms of muscular 
dystrophy, characterized by its hallmark symptom myotonia. DM is an autosomal 
dominant disease caused by a toxic gain of function RNA. The toxic RNA is produced 
from expanded non-coding CTG/CCTG repeats, and these CUG/CCUG repeats sequester 
a family of RNA binding proteins. The Muscleblind-like (MBNL) family of RNA 
binding proteins are sequestered to the expanded CUG/CCUG repeats. The MBNL 
proteins are regulators of alternative splicing, and their sequestration to the toxic RNA 
leads to mis-splicing events, which are believed to cause the symptoms observed in DM 
patients. 
A previously reported screen for small molecules used to identify compounds that 
could disrupt MBNL from binding the toxic CUG repeats found that pentamidine was 
able to rescue splicing defects associated with DM. Herein, we present a new class of 
molecules (phenolsulphonphthaleins) that inhibited MBNL1/CUG repeat complex 
formation in a competitive electrophoretic mobility shift assay (EMSA). Additionally, one 
of these molecules, bromophenol blue (BPB), acted in a synergistic manner with the 
previously described inhibitor pentamidine. We also demonstrated that the halogenation of 
the phenolsulphonphthalein dyes is an important factor for activity. Moreover, we present 
 v 
 
an analysis of a series of methylene linker variants of pentamidine that revealed 
heptamidine (an analog of pentamidine) could reverse splicing defects in a DM1 tissue 
culture model and rescue myotonia in a DM1 mouse model. 
Finally, we report on a new crystal structure of CUG repeats, crystallized in the 
context of a GAAA tetraloop/receptor which facilitated ordered packing within the 
crystal. This structure was consistent with previous structures showing that the repeats 
are essentially A-form RNA, despite having a U-U mismatch every third base pair. We 
also identified six types of U-U mismatch in the context of the 5’CUG/3’GUC motif, 
suggesting that the interactions between the uridines are dynamic. This structure also 
contains the highest resolution GAAA tetraloop/receptor structure (1.95 Å) reported to 
date. 
This dissertation includes previously unpublished co-authored material. 
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CHAPTER I 
INTRODUCTION 
 
Alternative splicing 
In order to create a proteome of millions of different proteins from a genome made up 
of only 20,000-25,000 genes (1), humans employ differential processing of mRNAs. 
After transcription from DNA, but before translation to protein, a pre-mRNA must be 
processed. This process includes splicing, a molecular process that results in the removal 
of non-coding introns and fusion of exons to create mature mRNAs. In order for splicing 
to occur, the splicing machinery, known as the spliceosome, must recognize key motifs in 
the pre-mRNA that indicate a sequence is intronic, and thus removed, or exonic, and 
retained (2). Of course, not every pre-mRNA is processed in the same manner every time. 
If this were true, then a single gene would code for only a single protein, which we know 
is not the case. Most exons are constitutively spliced, that is, they are always included in 
the mature mRNA. However, there are many regulated exons that are not constitutively 
spliced, but rather alternatively spliced (3), resulting in multiple mRNA isoforms being 
derived from a single gene. In the extreme example of the Drosophila gene Dscam, there 
are 38,016 potential isoforms (4). Although this is an extreme example, it is estimated 
that more than 90% of human transcripts are alternatively spliced (5). 
There are many different forms of alternative splicing (Figure 1). The most common 
type of alternative splicing event is the cassette exon, where an exon is either included or 
excluded from the final mRNA. There are also mutually exclusive exons, in which a 
choice between one of two exons is made. Exon length can also change by the use of 
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different 5’ or 3’ splice sites. Sometimes an intron will fail to be removed, leading to 
intron retention (3). 
 
 
 
 
Figure 1. Types of alternative splicing. A cassette exon event will either include or 
exclude an exon, while in the case of mutually exclusive exons, either one or the 
other exon will be included. Alternative 5’ and 3’ splice sites will utilize an 
alternative 5’ or 3’ splice site of an exon, respectively. In some cases, introns can fail 
to be spliced out, leading to intron retention.  
 
 
Alternative splicing is, necessarily, a highly regulated process involving a vast array 
of regulatory proteins and RNA motifs. Since different splice isoforms can result in 
proteins that have different biological activities, or that are targeted by nonsense-
mediated decay due to the introduction of a premature stop codon, it is easy to envision 
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how errors in alternative splicing can result in disease. Some alternative splicing diseases 
are caused by cis-factors, mutations to the RNA motifs that function as splicing signals, 
while others are due to trans-factors, changes in the proteins, or the levels of proteins, that 
regulate splicing (6). One such disease, which affects levels of proteins involved in the 
regulation of alternative splicing, is myotonic dystrophy. 
Myotonic dystrophy 
Myotonic dystrophy (DM) is the most common form of adult onset muscular 
dystrophy, characterized by many different symptoms including myotonia, muscle 
wasting, cataracts, cardiac conduction defects, and cognitive dysfunction, among others 
(7). There are two types of DM: type 1 (DM1) and type 2 (DM2). DM1 is caused by an 
aberrant expansion of CTG repeats in the 3’ untranslated region of the DMPK gene. 
Unaffected individuals have between 5 and 37 CTG repeats, while affected individuals 
have more than 50 (8). When transcribed, these expanded CUG repeats sequester RNA 
binding proteins in nuclear foci (Figure 2) (9, 10). The DM2 disease mechanism is very 
similar, except instead of a trinucleotide repeat, it is a tetranucleotide repeat (CCTG) 
expansion in the first intron of the ZNF9 gene (11). 
One of the families of proteins sequestered by CUG/CCUG repeats is the 
Muscleblind-like (MBNL) family of proteins (10). In humans, there are three paralogs: 
MBNL1, MBNL2, and MBNL3. Within this body of work, I discuss studies focused 
primarily on MBNL1, since an MBNL1 knockout mouse has been shown to phenocopy 
DM (12). The MBNL proteins are zinc-finger RNA binding proteins that regulate 
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Figure 2. Characteristic nuclear foci observed in DM composed of RNA and proteins. 
(A) Nucleus of a HeLa cell expressing CUG repeats and MBNL1. Blue DAPI stains 
the DNA, and the foci are white. (B) Foci are composed of CUG repeat RNA and 
various RNA binding proteins, including MBNL. (C) Molecular structure of a duplex 
of six CUG repeats. The CUG repeats are essentially A-form in solution, despite 
having a U-U mismatch every third base pair. 
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alternative splicing (13). When sequestered to CUG/CCUG repeats, they are no longer 
able to properly regulate their target transcripts (14-18). Many of the mis-splicing events 
in DM have been found to be MBNL dependent, and some of these events have been 
correlated with disease symptoms. One target of the MBNL proteins is the Clcn1 gene, 
which encodes a chloride ion channel. The MBNL proteins are negative regulators of 
exon 7a in Clcn1 (when MBNL proteins are present, exon 7a is excluded). In the 
presence of CUG/CCUG repeats, the levels of free MBNL are not sufficient to properly 
regulate splicing of exon 7a (Figure 3A). This leads to chloride channelopathy and the 
characteristic DM symptom myotonia (19). Several other MBNL regulated mis-splicing 
events in DM have been well characterized, including TNNT2 (14, 16), INSR (17), and 
Atp2a1 (15). MBNL promotes the exclusion of exon 5 in TNNT2, resulting in the 
expression of the adult isoform (Figure 3B). MBNL can also act as a splicing enhancer as 
it does in the cases of INSR (Figure 3C) and Atp2a1 (Figure 3D). 
 
 
Figure 3 (next page). Schematic of alternative splicing events in the presence and 
absence of MBNL. (A) MBNL mediated alternative splicing of Clcn1. When MBNL 
is present, exon 7a is skipped, resulting in a functional chloride channel protein. 
When MBNL is not present, perhaps due to sequestration by CUG/CCUG repeats, 
exon 7a is included. Exon 7a contains a premature stop codon, resulting in 
degradation of the transcript by the nonsense mediated decay pathway. (B) MBNL 
mediated alternative splicing of TNNT2. In the presence of MBNL, exon 5 is 
excluded, leading to the expression of the adult isoform of TNNT2; however, when 
MBNL is absent, exon 5 is skipped resulting in the fetal isoform. (C) MBNL 
mediated alternative splicing of INSR. MBNL binding promotes exon 11 inclusion, 
resulting in an insulin receptor that only binds to insulin, while exon 11 exclusion (in 
the absence of MBNL) produces an insulin receptor that can bind to both insulin and 
insulin-like growth factor-II. This contributes to the insulin resistance phenotype 
observed in DM patients. (D) MBNL mediated alternative splicing of Atp2a1. MBNL 
facilitates the inclusion of exon 22, leading to the adult isoform. 
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Since many mis-splicing events have been shown to be MBNL dependent, one 
potential method of alleviating disease symptoms would be to release MBNL from the 
CUG/CCUG repeat foci, so that it could be free within the cell to perform its proper role 
in splicing regulation. There are many potential methods of displacing MBNL including 
utilizing small molecules (20-23), multivalent compounds (24-26), small peptides (27, 
28), or antisense oligonucleotide analogs (29). Because most FDA approved drugs are 
small molecules (30), and because there are many small molecule drugs that bind RNA 
(31), we decided to take a small molecule approach to relieving MBNL sequestration. 
Pentamidine as a potential DM1 therapeutic 
In order to identify small molecules that have the potential to disrupt MBNL/CUG 
complexes, we undertook a screen of ~30 molecules that are known to interact with 
nucleic acid. Using a competitive electrophoretic mobility shift assay (EMSA), we 
discovered a small molecule, pentamidine (a currently FDA approved drug for the 
treatment of Pneumocystis carinii infections), had the ability to disrupt the 
MBNL1/(CUG)4 complex with an IC50 of 58 ± 5 µM (20) (Figure 4A). In addition to 
disrupting the complex in vitro, pentamidine was also able to reverse splicing defects 
(Figure 4B) and reduce the number the nuclear foci in a HeLa cell model of DM1 (Figure 
4C). Furthermore, when mice that express 220 CUG repeats under a human skeletal actin 
promoter were treated with pentamidine, partial splicing rescue of two endogenous 
mRNAs, including Clcn1 exon 7a, were observed (Figure 4D). 
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Figure 4. Pentamidine disrupts the MBNL1/(CUG)4 complex in vitro and rescues mis-
splicing in vivo. (A) EMSA showing MBNL1 binds to (CUG)4, a short hairpin RNA. 
When pentamidine is added, it disrupts the MBNL1/(CUG)4 complex with an IC50 of 
58 µM. (B) Pentamidine rescues the mis-splicing of two transiently transfected 
minigenes in a DM1 HeLa cell model. (C) Pentamidine reduces the number of 
nuclear foci in cells expressing 960 CUG repeats, freeing MBNL1 within the nucleus. 
(D) DM1 mice treated with pentamidine show mis-splicing rescue of two endogenous 
transcripts. 
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Myotonic dystrophy and RNA structure 
Since the expanded CUG repeats are the causative agent of DM1, their structure has 
been the object of much interest since the discovery of their toxic nature. The first studies 
on CUG structure were probing experiments that found that extended CUG repeats 
formed hairpin structures (32). The first crystal structure of the CUG repeats showed that, 
despite having a U-U mismatch every third base pair, the structure was essentially A-
form (Figure 2C) (33). This structure also found that the U-U mismatches formed one 
hydrogen bond, and did not distort the backbone of the RNA, as other U-U mismatches 
had been observed to do (34). Since the first crystal structure, several other crystal 
structures of CUG repeat RNA have been released (35, 36), as well as an NMR structure 
(37), confirming the A-form nature of CUG repeats. These structures also found that the 
U-U mismatches in the 5’CUG/3’GUC motif were not strictly locked in to the single 
hydrogen bond conformation. 
Understanding the structure of CUG repeats may help us understand how MBNL 
proteins recognize the YGCY motif (38) through the Watson-Crick face of the GC 
dinucleotide (39), but in the context of double-stranded RNA these faces of the 
nucleotides are not available for binding by MBNL proteins. Additionally, knowing the 
structure of CUG repeats and how they interact with small molecules, can help guide 
rational drug design. 
In order to improve upon our initial lead compound pentamidine, we undertook a 
structure activity relationship (SAR) study. In Chapter II, I discuss complications 
surrounding the original screening assay and demonstrate that pentamidine needs a 
“helper” compound in order to efficiently disrupt the MBNL1/(CUG)4 complex in the 
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competitive EMSA. Chapter III and Appendix A discuss the SAR study performed on 
pentamidine methylene linker analogs using the original competitive EMSA and an in 
vivo splicing assay. We show that as the methylene linker length increases, compounds 
are more effective at disrupting the MBNL1/(CUG)4 complex in vitro, and also rescue the 
mis-splicing of two different MBNL targets in a HeLa cell model of DM1. Additionally, 
we observed that heptamidine (a derivative of pentamidine containing a seven carbon 
methylene linker) was able to reverse myotonia in a DM1 mouse model. In Chapter IV, I 
crystallized CUG repeats utilizing a crystallization module in order to facilitate 
intermolecular contacts and analyze the flexibility of the U-U mismatch within the 
context of the 5’CUG/3’GUC motif. Chapters II, III, and IV contain unpublished, 
co-authored material. 
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CHAPTER II 
A NEW CLASS OF SMALL MOLECULES DISRUPTS MBNL1/CUG REPEAT 
BINDING AND WORKS SYNERGISTICALLY WITH PENTAMIDINE  
 
I was the primary contributor to the experiments described in the following chapter 
and did all of the writing. Dr. J. Andrew Berglund was the principal investigator of this 
work. 
INTRODUCTION 
Myotonic dystrophy (DM) is an autosomal dominant disorder caused by a toxic, gain-
of-function RNA. In myotonic dystrophy type 1 (DM1), there is an expansion of a CTG 
trinucleotide repeat in the 3’ UTR of the DMPK gene. Unaffected individuals have 
between 5 and 37 CTG repeats, whereas DM1 patients have 50 or more. Upon 
transcription, these CTG repeats form stable, structured CUG duplex RNA which 
aberrantly interacts with many different nuclear proteins. One of the proteins that binds 
the CUG repeats is Muscleblind-like 1 (MBNL1), a regulator of alternative splicing 
(reviewed in ref (40)). MBNL1 has been shown to co-localize with the CUG repeats in 
the nuclear foci that are a hallmark of DM (41). Additionally, MBNL1 has been shown to 
directly interact with CUG repeats in vitro (16, 42, 43). Thus, MBNL1 is sequestered to 
this expanded RNA and less available to perform its function of regulating alternative 
splicing events (14-18). It is this sequestration of MBNL1 that leads to mis-splicing 
events observed in DM1, a number of which have been correlated with disease symptoms 
(reviewed in refs (40, 44)). 
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We previously described a small molecule screen used to identify small molecule 
inhibitors of the CUG/MBNL1 interaction (20).  The screen used a competitive 
electrophoretic mobility shift assay (EMSA) wherein the amount of MBNL1 and (CUG)4 
(a small hairpin RNA composed of two CUG repeats, a UUCG cap, and two more CUG 
repeats) were held constant. As molecules were added, those effective at disrupting the 
MBNL1/(CUG)4 complex resulted in an increase in free RNA. We discovered that 
pentamidine (a currently FDA approved drug for the treatment of Pneumocysitis carinii 
infections) is able to disrupt MBNL1/(CUG)4 binding with an IC50 of 58 ± 5 µM. We 
further showed that in an in vivo HeLa cell splicing system, pentamidine is able to rescue 
mis-splicing events caused by the presence of 960 CUG repeats and to disrupt the 
characteristic nuclear foci observed in DM1. Finally, when pentamidine is administered 
to mice that express 250 CUG repeats, partial reversal of DM-related splicing defects is 
observed. From this study, it was evident that a small molecule approach to treating DM1 
has the potential to be successful, since pentamidine has the ability to disrupt the 
MBNL1/CUG complex in vitro and to presumably do the same in both HeLa cells and 
mouse tissue to reverse splicing defects. 
During subsequent studies of the pentamidine/CUG repeat interaction, we discovered 
that the concentration of dye in the EMSA dramatically altered the effectiveness of 
pentamidine. This observation lead to the discovery that bromophenol blue (BPB) is able 
to compete with the MBNL1/(CUG)4 complex on its own, as well as synergistically with 
pentamidine. An SAR study of BPB showed that iodophenol blue (IPB) demonstrates an 
approximately 7.5-fold increase in efficacy over BPB. Other methods can disrupt the 
MBNL1/CUG repeat complex, including oligonucleotide analogs and several different 
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small molecules (reviewed in ref (45-47)), but phenolsulphonphthaleins are unique 
because it appears this class of compounds function through a different mechanism than 
the previously described molecules. 
RESULTS and DISCUSSION 
BPB disrupts the MBNL1/(CUG)4 complex. While optimizing conditions for the 
competitive EMSA, we discovered that BPB, the dye used to monitor reaction mixtures 
and progress through the polyacrylamide matrix, acted to disrupt the MBNL1/(CUG)4 
complex with an IC50 of 945 ± 30 µM (Figure 5). 
 
 
 
 
Figure 5. Titration of BPB. (a) EMSA of the competition of BPB with the 
MBNL1/(CUG)4 complex at 0, 100, 200, 300, 400, 600, 800, 1200, 1600, 2000, and 
2400 µM BPB. (b) IC50 curve of BPB competition with MBNL1. 
 
 
 
Since BPB is an anionic molecule at the pH at which the competitive EMSA is 
performed, it is almost certainly disrupting the complex differently than pentamidine. We 
suspect that BPB is interacting with the protein rather than the negatively charged RNA. 
Additionally, BPB is known to interact with other proteins (48-51), so it is likely BPB is 
interacting with MBNL and disrupting its RNA binding ability. 
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BPB and pentamidine work synergistically. Since BPB and pentamidine probably act 
through different mechanisms to disrupt the MBNL1/(CUG)4 complex (pentamidine is 
suspected of interacting with the RNA), we decided to test them together, to observe if 
pentamidine and BPB could act simultaneously. Interestingly, when BPB and 
pentamidine are both present in the in vitro assay, they act synergistically: in the presence 
of 38 µM pentamidine, the IC50 of BPB drops to 376 µM (Figure 6, Table 1), compared 
to an IC50 945 ± 30 µM with BPB alone. The same is true of pentamidine: with 
increasing concentrations of BPB, pentamidine appears to be more effective at disrupting 
the complex (Figure 6a). In fact, under these assay conditions, ≥200 µM BPB is required 
for pentamidine dependent complex disruption (Figure 6b). With increasing BPB 
concentrations, the effect of pentamidine is magnified, from complete loss of efficacy 
without BPB, to an IC50 of 15 µM at 1200 µM BPB (Figure 6b, Table 1). Thus it is clear 
that pentamidine and BPB are working synergistically in the EMSA assay to disrupt the 
MBNL1/(CUG)4 complex. 
 
Table 1. IC50 values of pentamidine with varying concentrations of BPB and BPB with 
varying concentrations of pentamidine. 
 
Pentamidine titrations Bromophenol blue titrations 
[BPB] IC50 pent [pent] IC50 BPB 
0 µM – 0 µM 945 ± 30 µM 
100 µM – 6.6 µM 925 ± 56 µM 
200 µM 84 ± 3 µM 11 µM 892 ± 60 µM 
300 µM 46 ± 2 µM 17 µM 823 ± 40 µM 
400 µM 36 ± 3 µM 22 µM 663 ± 77 µM 
600 µM 27 ± 1 µM 26 µM 516 ± 47 µM 
800 µM 23 ± 2 µM 32 µM 426 ± 37 µM 
1200 µM 15 ± 3 µM 38 µM 347 ± 17 µM 
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Figure 6. Pentamidine (pent) and bromophenol blue (BPB) titrations. (a) EMSA of the 
competition of pentamidine and BPB with the MBNL1/(CUG)4 complex. In the 
absence of BPB, it is clear that pentamidine has no effect on disrupting the 
protein/RNA complex. As the BPB concentration increases, pentamidine is better 
able to free the (CUG)4 RNA. At high concentrations of both BPB and pentamidine, 
precipitation was observed, both as an increase in the number of counts in the wells 
and by a blue precipitate in the wells. These points were excluded. (b) IC50 curves for 
each concentration of BPB (left graph) and pentamidine (right graph). 
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There are several potential mechanisms to account for the synergistic effect of 
pentamidine and BPB on the MBNL1/CUG repeat interaction. It is possible that BPB 
decreases the affinity of MBNL1 for the CUG RNA enough so that the effect of 
pentamidine is more easily observed. This could take place through binding interactions 
with MBNL1. BPB is known to interact with other proteins, so it is plausible that BPB is 
able to interact with MBNL1 and lessen its affinity for RNA. Another possibility is that 
BPB and pentamidine form an ion pair, since, at physiological pH, BPB carries a 
negative charge on the arylsulfonate group, and pentamidine has a positive charge on 
each of the amidine groups. If formed, this ion pair could target the RNA better than 
either pentamidine or BPB alone. In an effort to identify important structural features of 
BPB, we decided to test dyes similar to BPB to determine if we could identify more 
potent inhibitors and gain insight into the mechanism of inhibition. 
Dye efficacy depends on ring halogenation. BPB is a pH indicator composed of two 
brominated phenolic rings and a benzene sulfonyl ring joined by a single carbon. We 
found many other commercially available indicators that had substitutions at the 
position(s) of the bromines. These indicators substituted other halogens, were mono-
halogenated, or had no halogens. Each of these dyes was tested for its ability to disrupt 
the MBNL1/(CUG)4 complex alone and with 50 µM pentamidine. Phenol red (PR), 
which has no halogens, failed to compete both on its own and with pentamidine (Figure 
7a). The same was true of bromophenol red (BPR) and chlorophenol red (CPR), which 
both have only one halogen on each of the phenol groups (Figure 7a). Chlorophenol blue 
(CPB), with two chlorines on each phenol group, was not able to compete with the 
MBNL1/(CUG)4 complex on its own (Figure 7); however, with the addition of 50 µM 
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pentamidine, it was able to disrupt the complex with an IC50 of 1166 ± 255 µM. As 
expected, BPB was able to compete on its own (IC50 = 945 ± 30 µM) and with in-creased 
efficacy in the presence of pentamidine (IC50 = 276 ± 30 µM). Of all the BPB derivatives, 
iodophenol blue (IPB), which has two iodines on each phenol group, performed the best. 
It had an IC50 of 127 ± 17 µM alone and an IC50 of 107 ± 26 µM with pentamidine 
(Figure 7a), demonstrating only a modest, if any, increase in efficacy in the presence of 
pentamidine (Figure 7b). 
The increase in complex disruption efficacy observed when pentamidine and a 
phenolsulphonphthalein dye are together is clearly affected by the halogenation of the 
dye. There seems to be an inverse relationship between electronegativity and ability to 
compete; the chlorinated dye (CPB), which is the most electronegative, is the least 
effective, while the iodinated (IPB) dye is the most effective and the least 
electronegative. 
 
 
Figure 7 (next page). Titrations of dyes with and without pentamidine. (a) EMSA of the 
competition with the MBNL1/(CUG)4 complex of the six dyes alone and with 50µM 
pentamidine. All dyes, with the exception of PR and IPB were tested at the 
concentrations 0, 100, 200, 300, 400, 600, 800, and 1200µM. PR was tested at 0, 100, 
200, 300, 400, 600, and 800µM due to solubility issues and IPB was tested at 0, 25, 
50, 60, 75, 100, 150, 200, and 300µM since it was much more effective than any of 
the other dyes. PR clearly has no effect, alone or with pentamidine, while CPB and 
BPR may be beginning to compete at their highest concentrations. CPB, while no 
observable competition is taking place with the dye alone, when added to 
pentamidine, together they are able to compete quite well. IPB is the best competitor 
of the group, and shows only modest increases in efficacy in the presence of 
pentamidine. (b) IC50 curves of for each dye alone (left graph) and with 50µM 
pentamidine (right graph). The most drastic changes are observed with CPB and BPB. 
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We suspect that CPB, BPB, and IPB are somehow interacting with MBNL1, 
sufficiently weakening the interaction between MBNL1 and (CUG)4 so that 
pentamidine’s effect can be observed in vitro. Although pentamidine does not effectively 
inhibit the MBNL1/(CUG)4 complex in the EMSA in the absence of dyes, pentamidine 
works quite will in both HeLa cells and a DM1 mouse model (20). Initially, we 
considered the possibility that PR and pentamidine were working together in cell culture, 
since PR is used as a pH indicator in the growth media, but that appears unlikely based on 
the EMSA results. No dyes were added in the mouse studies with pentamidine, 
suggesting in the cell/animal environment, pentamidine is either more “potent” or an 
endogenous molecule(s) replaces the dyes. 
Interestingly, we have discovered a new class of compounds able to disrupt 
MBNL1/CUG complexes. Although there is no existing treatment for DM1, many 
different approaches are currently being developed. Many focus on displacing MBNL 
from the CUG repeat structures, either through utilizing small molecules (20, 21), 
multivalent compounds (25), small peptides (27), or antisense oligonucleotide analogs 
(29). Other techniques include cleaving the CUG repeats (52-54) or triggering their 
degradation (55-57). The phenolsulphonphthalein class of compounds is unique because, 
based on literature precedence, (48, 49, 51, 58) we believe it is acting on the protein 
rather than the nucleic acid. We have already been able to make significant improvements 
over the lead compound BPB. By simply replacing the bromines of BPB for the iodines 
of IPB, we have observed 7.5 fold decrease in the IC50 of IPB as compared to BPB. It 
may well be worth further optimizing BPB-like compounds, or investigating other 
halogenated ring systems. More importantly, we are now aware of the in vitro dye effect, 
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and can properly control for it in future drug comparison studies searching for 
pentamidine analogs with better efficacy. Determining if dye-like molecules are working 
in the cell to aid pentamidine (and potentially other small molecule inhibitors), and 
identifying these compounds are important questions to address in the future. 
METHODS 
MBNL1 purification. The MBNL1 1-260 protein was purified as previously 
described (20) with the following changes. After purification, the protein was dialyzed 
into 500 mM NaCl, 20 mM Tris pH 7.5, 50% glycerol, and 5 mM β-mercaptoethanol. 
Aliquots were stored at –80 °C until just before use. 
RNA labeling. The (CUG)4 RNA construct used in gel shifts (5’–
GCUGCUGUUCGCUGCUG) was ordered from IDT and 5’ labeled using [γ–32P]ATP. 
After kinasing, the RNA was run over a spin column containing Bio-Gel P2 Gel, brought 
to final stock concentration of 50 nM using low TE, and stored at –20 °C until use. 
Gel shift assay. Kinased (CUG)4 RNA was snap annealed in 250 mM NaCl, 25 mM 
MgCl2, and 75 mM Tris pH 7.5 by heating at 95 °C for 3 minutes. The reaction was 
placed on ice for 5 minutes, BSA and heparin were added, and the reaction placed back 
on ice for another 5 minutes. MBNL1 was then added to the RNA, and incubated at room 
temperature (RT) for 10 minutes. Pentamidine or water was added, followed by another 5 
minute RT incubation, followed by the addition of dye. The final reaction volume of 10 
µL was incubated at RT for 25 minutes. Final reaction conditions were 0.5 nM (CUG)4, 
175 mM NaCl, 20 mM Tris pH 7.5, 5 mM MgCl2, 2 mg mL-1 BSA, 0.1 mg mL-1 heparin, 
1.25 mM β-mercaptoethanol, 1.25% glycerol, and 250 nM MBNL. Then 3 µL of the 
reaction was run on a 5% 80:1 pre-chilled polyacrylamide gel with 0.5x TB. Gels were 
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run at 4 °C at 170V for 35 minutes, dried and autoradiographed. IC50 values were 
calculated as previously described (Warf, 2009). In brief, gels were quantified using 
ImageQuant (Molecular Dynamics). The percent of RNA bound was determined by 
taking the ratio of the RNA:protein complex (including any well shifting) to the total 
RNA, per lane. To determine the IC50, the equation 
 ! = !!1+ !!!! !! 
 
was used, where m0 = small molecule concentration, m1 = IC50, m2 = Hill coefficient, and 
m3 = fraction of MBNL bound without small molecule present. When present, errors 
were determined by calculating the standard deviation of triplicate data. 
Pentamidine was purchased from Sigma-Aldrich as the isethionate salt, converted to 
the chloride salt, and dissolved in water. PR, CPR, BPR and IPB (3’, 3”, 5’, 5”-
tetraiodophenolsulfonphthalein) were purchased from TCI, CPB was purchased from 
City Chemical, and BPB was purchased from Sigma. Dyes were dissolved in water with a 
small amount of NaOH to help with solubility and bring to a neutral pH. 
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CHAPTER III 
STRUCTURE OPTIMIZATION REVEALS A SMALL MOLECULE THAT 
REVERSES THE SPLICING DEFECTS AND MYOTONIA IN A MOUSE 
MODEL OF MYOTONIC DYSTROPHY 
 
I was the primary contributor to the experiments described in the following chapter 
and did all of the writing. Dr. Masayuki Nakamori performed all the experiments 
involving mice. Dr. Cameron Hilton and Dr. Micah Bodner synthesized the small 
molecules. Dr. Michael Haley and Dr. Charles Thornton helped design experiments, and 
Dr. J. Andrew Berglund was the principal investigator of this work. 
INTRODUCTION 
Myotonic dystrophy (DM) is characterized by many different symptoms, including, 
but not limited to, cataracts, cardiac conduction defects, cognitive dysfunction, muscle 
wasting, and, its hallmark symptom, myotonia, where muscles have delayed relaxation. 
There are two types of DM: type 1 (DM1) and type 2 (DM2). DM1 is caused by the 
aberrant expansion of CTG repeats in the 3’ UTR of the DMPK gene. Unaffected 
individuals have between 5 and 37 repeats, whereas DM1 patients have more than 50 
repeats. Upon transcription, these repeats form a CUG repeat stem loop RNA, which is 
capable of sequestering RNA binding proteins in nuclear foci. Similar circumstances 
cause DM2, where CCTG repeats in the first intron of the ZNF9 gene expand and lead to 
production of a CCUG repeat stem loop (reviewed in refs (40, 59)).  
One of the protein families capable of binding these CUG/CCUG repeats is the 
Muscleblind-like (MBNL) family of proteins (10). In humans, there are three paralogs: 
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MBNL1, MBNL2, and MBNL3. The MBNL proteins are zinc-finger RNA binding 
proteins that regulate alternative splicing events (13). When extended CUG/CCUG 
repeats are present, MBNL proteins are sequestered to the repeat RNA and are no longer 
able to properly regulate alternative splicing of their target transcripts (14-18). Many of 
the mis-splicing events observed in DM are MBNL dependent, and some of these events 
have been correlated with disease symptoms. One target of the MBNL proteins is the 
Clcn1 gene, which encodes a chloride ion channel. The MBNL proteins are negative 
regulators of exon 7a in Clcn1 (when MBNL proteins are present, exon 7a is excluded). 
In the presence of CUG/CCUG repeats, the levels of free MBNL are not sufficient to 
properly regulate splicing of exon 7a. This leads to chloride channelopathy and the 
characteristic DM symptom myotonia (19). 
Although there are currently no treatments available to patients with DM, many 
different approaches are under development. Several methods focus on displacing MBNL 
proteins from the CUG/CCUG repeat structures, either through utilizing small molecules 
(20-22, 22, 23), multivalent compounds (24-26), small peptides (27, 28), or antisense 
oligonucleotide analogs (29). Other techniques include cleaving the repeats (52-54) or 
triggering their degradation (55-57, 60). We have recently discovered that pentamidine, 
an FDA approved drug for treatment of Pneumocystis carinii infections, disrupts 
MBNL1/(CUG)4 interactions in a competitive electrophoretic mobility shift assay 
(EMSA) (20). Pentamidine also rescues mis-splicing of transiently transfected minigene 
reporters in a HeLa DM1 cell model expressing 960 interrupted CUG repeats. Most 
encouragingly, pentamidine was used to improve mis-splicing of endogenous transcripts 
in a DM1 mouse model expressing 220 CUG repeats. From this study, it was evident that 
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a small molecule approach for treating DM1 has the potential to be successful since 
pentamidine has the ability to rescue splicing defects in both HeLa cells and mouse 
tissue. 
In an effort to develop a pentamidine analog with improved physiochemical 
properties, we undertook a structure activity relationship (SAR) study. Analogs 
containing between three to nine methylene carbons were synthesized and tested using 
the in vitro EMSA assay for their ability to rescue the mis-splicing of MBNL regulated 
minigenes in our HeLa cell splicing assay. In general, analogs with more methylenes 
more efficiently rescued splicing. The most promising compound, heptamidine, was 
tested for its ability to rescue mis-splicing and myotonia in a transgenic mouse model of 
DM1. 
RESULTS and DISCUSSION 
Pentamidine analogs rescue two mis-spliced minigenes in tissue culture. A 
common tactic to improve the physiochemical properties of a drug candidate is to vary 
the hydrophobicity of the molecule, and we utilized this strategy by varying the length of 
pentamidine’s methylene linker. The most polar analog was propamidine, with a three 
carbon linker, and the least polar was nonamidine, with a linker of nine carbons (Figure 
8). During our studies with pentamidine, we discovered that a dye, bromophenol blue 
(BPB), used to aid in gel loading/tracking, was necessary for pentamidine to robustly 
inhibit the MBNL1/(CUG)4 interaction. In fact, BPB was able to dissociate the 
MBNL1/(CUG)4 complex in the absence of pentamidine (Figure 9a, b). Additionally, we 
observed that BPB and pentamidine were able to function synergistically in the 
electrophoretic mobility shift assay (EMSA) (Figure 9c). That is, with increasing 
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concentrations of BPB, pentamidine appeared to be more effective at disrupting the 
MBNL1/(CUG)4 complex. Due to this complication in the EMSA, we decided to use our 
DM1 cell model for screening the activity of the methylene linker analogs. 
 
 
 
 
Figure 8. Structure of the pentamidine analogs. Methylene carbon linker highlighted by 
gray parenthesis. 
 
 
 
 
 
Figure 9. Titration of BPB and synergy with pentamidine. (a) EMSA of the competition 
of BPB with the MBNL1/(CUG)4 complex at 0, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8, 1.2, 1.6, 2, 
and 2.4 mM BPB. (b) IC50 curve of BPB competition with MBNL1. (c) Plot of the 
IC50 of pentamidine at 0.2, 0.3, 0.4, 0.6, 0.8, and 1.2 mM BPB (at 0 and 0.1 mM BPB, 
pentamidine did not disrupt the MBNL1/(CUG)4 complex in the EMSA). As BPB 
concentration increases, the IC50 of pentamidine decreases. Error bars denote the 
standard deviation of at least three observations. 
 
 
 
 
Each analog was tested for the ability to rescue splicing of transiently transfected 
minigenes in a HeLa cell model of DM1. Two different minigenes containing exons that 
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are mis-spliced in DM were tested: TNNT2 (also known as cTNT), containing the 
alternatively spliced exon 5, and INSR, containing the alternatively spliced exon 11. 
MBNL proteins facilitate exclusion (negative regulation) of exon 5 of TNNT2: when 
MBNL proteins are present, exon 5 is excluded. The typical level of exon 5 inclusion 
when the TNNT2 minigene is expressed in HeLa cells is 64 ± 2%. The inclusion level 
increased to 82 ± 3% when HeLa cells co-expressed a DMPK plasmid containing 960 
CUG repeats (Figure 10a). Presumably, this change in TNNT2 exon 5 inclusion is due to 
the sequestration of endogenous MBNL proteins to the CUG repeats. Propamidine did 
not have the desired effect on TNNT2 mis-splicing at concentrations up to 130 µM 
(higher concentrations were toxic). Also unable to rescue splicing defects before causing 
significant cell death (at 4 µM) was nonamidine. The remaining linker analogs rescued 
TNNT2 mis-splicing to varying degrees. The concentration needed to observe 50% rescue 
(EC50) for butamidine was 23 ± 5 µM, which was similar to pentamidine (EC50 = 20 ± 4 
µM). Interestingly, at higher concentrations, butamidine and pentamidine lowered exon 5 
inclusion levels below that of wild type. Hexamidine and heptamidine showed 
improvements over pentamidine with EC50 values of 12 ± 3 µM and 15 ± 6 µM, 
respectively. Finally, octamidine showed a slight rescue of TNNT2 mis-splicing; 
however, because of toxicity issues, it was not possible to treat the cells with high enough 
concentrations to obtain an accurate EC50 value (Figure 10b). Thus, hexamidine is able to 
rescue TNNT2 mis-splicing at the lowest dose compared to other linker analogs. 
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Figure 10. Pentamidine analogs rescue mis-splicing of TNNT2 minigene reporter in a 
HeLa cell DM1 model. (a) RT-PCR data of TNNT2 splicing. Errors are standard 
deviation. (b) Jitter plot representation of TNNT2 splicing. Each point is one 
experiment and the line represents the average of all experiments for that condition 
(at least three for each concentration). Butamidine, pentamidine, hexamidine, and 
heptamidine rescue TNNT2 mis-splicing in the presence of 960 CUG repeats. 
Octamidine may have a slight effect. Gray area denotes range between typical 
splicing and DM mis-splicing. 
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Figure 11. Pentamidine analogs rescue mis-splicing of INSR minigene reporter in a HeLa 
cell DM1 model. (a) RT-PCR data of INSR splicing. Errors are standard deviation. (b) 
Plots of INSR splicing. All pentamidine linker analogs are able to fully or partially 
rescue INSR mis-splicing in the presence of 960 CUG repeats. Gray area denotes 
range between typical splicing and DM mis-splicing. 
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We also tested the ability of the linker analogs to rescue an exon that is positively 
regulated by MBNL proteins: exon 11 of the INSR gene. When wild type HeLa cells 
expressed the INSR reporter minigene, exon 11 inclusion was 71 ± 1%. When 960 CUG 
repeats were co-expressed with the INSR reporter, exon 11 inclusion dropped to 48 ± 7% 
(Figure 11a). Unlike the TNNT2 study, all linker analogs were able to partially or fully 
rescue the mis-splicing of exon 11 of INSR when CUG repeats were expressed (Figure 
11b). Propamidine rescued mis-splicing with an EC50 of 64 ± 10 µM. Butamidine and 
pentamidine were similar with EC50 values of 34 ± 7 µM and 31 ± 2 µM, respectively. 
Hexamidine also rescued INSR mis-splicing (EC50 = 15 ± 1 µM), as did heptamidine 
(EC50 = 9 ± 1 µM). Unlike with the TNNT2 minigene, both octamidine and nonamidine 
rescued INSR mis-splicing with EC50 values of 7 ± 1 µM and 6 ± 1 µM. 
All the compounds were able to partially or fully rescue INSR mis-splicing, while 
only butamidine, pentamidine, hexamidine, and heptamidine rescued TNNT2. One 
possible explanation for this observation is that different MBNL targets require different 
concentrations of MBNL proteins in the cell to be properly regulated. For example, 
nonamidine is toxic to HeLa cells at concentrations above 4 µM. TNNT2 is not rescued; 
however, INSR is rescued by 30%. Presumably, the same amount of MBNL proteins are 
freed inside the cell, so the difference in rescue observed between the two minigenes is 
likely due to the amount of MBNL required for proper splicing regulation. Interestingly, 
when rescue was observed with TNNT2, those compounds had slightly lower EC50 values 
as compared to INSR (Figure 12). Additionally, TNNT2 exon 5 inclusion was often 
decreased to inclusion levels that are lower than wild type (Figure 10b), suggesting that 
these compounds may function to block exon 5 inclusion of the TNNT2 pre-mRNA, 
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possibly by interacting with the TNNT2 pre-mRNA (20). The effect of pentamidine and 
its analogs on the splicing of the TNNT2 pre-mRNA does not appear to be a general 
phenomenon, because splicing of INSR and other pre-mRNAs tested were not altered by 
pentamidine in the absence of CUG repeats (61). 
 
 
 
Figure 12. Plot of EC50 values versus methylene linker length. When INSR splicing is 
monitored, the inverse relationship between methylene linker length and EC50 holds. 
The trend is less clear with TNNT2. Error bars are standard deviation. 
 
 
As linker length increases, we observe an increase in efficacy, but we also observe an 
increase in toxicity to HeLa cells. This could be due to the increased lipophilicity of the 
molecule as the carbon chain becomes longer. While pentamidine satisfies some of 
Lipinski’s “rule of 5” requirements for orally available drug-like compounds (62), its 
constitutively charged amidines hinder its ability to diffuse through membranes. As linker 
length increases, the hydrophobicity of the molecule also increases. Thus, the compounds 
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with longer linkers may cross the membrane more effectively, resulting in increased 
intracellular concentrations, leading to increased efficacy and toxicity observed in the 
HeLa cell splicing assay. 
Heptamidine rescues mis-splicing in a DM1 mouse model and reduces myotonia 
symptoms. Because heptamidine rescued mis-splicing of both minigenes in HeLa cells 
while retaining water solubility, it was tested in the HSALR transgenic DM1 mouse model. 
The HSALR DM1 mouse model expresses 220 CUG repeats under the skeletal promoter 
(63). Two different endogenous pre-mRNAs were observed: Clcn1, the mis-splicing of 
which has been shown to cause myotonia (19), and Atp2a1 (also called Serca1), which is 
a robust marker of mis-splicing in DM (64). MBNL proteins have been shown to promote 
exclusion of exon 7a of the Clcn1 gene. Wild type adult mice included exon 7a of the 
Clcn1 pre-mRNA at a level of 4 ± 1% while HSALR mice included exon 7a at steady state 
levels of 47 ± 1% (Figure 13, note that exon 7a inclusion isoforms are subject to 
nonsense mediated decay). Treatment with heptamidine caused a dose-dependent 
reduction of exon 7a inclusion in HSALR mice, returning to wild type levels (6 ± 1%) at 
the dose of 20 mg kg-1 heptamidine (Figure 13). 
The MBNL regulated exon of Atp2a1 (exon 22) is included in the presence of MBNL 
proteins (positively regulated). Wild type adult mice included this exon at 100 ± 1% 
(Figure 13). When MBNL proteins are sequestered by the 220 CUG repeats present in 
HSALR mice, exon 22 inclusion dropped to 23 ± 3%. Although full rescue with 
heptamidine could not be reached, under a treatment regimen of 30 mg kg-1 per day for 
7 d, exon 22 inclusion levels returned to 62 ± 4% (Figure 13). Additionally, after being 
treated with 30 mg kg-1 heptamidine for 7 d, mice went untreated for 10 d, and splicing of 
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Clcn1 and Atp2a1 was examined. In both mRNAs, exon inclusion levels returned to 
control HSALA levels (Figure 13). 
 
 
 
 
Figure 13. Heptamidine rescue of endogenous mis-splicing events in HSALR mice. Clcn1 
showed a complete rescue by 20 mg/kg for 7 d. Each symbol represents the splicing 
outcome for vastus muscle of a single mouse. After treatment, withdrawal mice (WD) 
were maintained for 10 d with no additional heptamidine injections. These mice 
showed a complete return to disease state splicing. Atp2a1 showed partial rescue of 
mis-splicing. At 30 mg/kg heptamidine, exon 22 inclusion is approximately 50% 
rescued. WD mice again reverted to the pre-treatment splicing levels. Errors are 
standard deviation. Gray area denotes range between typical splicing and DM 
mis-splicing. 
 
 
In addition to splicing defects, HSALR mice exhibit myotonia, manifested by runs of 
repetitive action potentials. We graded the severity of myotonia by insertion of 
extracellular recording electrodes into muscle tissue (electromyography) under general 
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anesthesia. In glucose-treated controls, we observed grade 3 myotonia in vastus muscle, 
which indicates abundant repetitive discharges with nearly all electrode insertions. When 
treated with 20 or 30 mg kg-1 heptamidine, the myotonia was reduced from grade 3 to 
grade 1 (occasional myotonic discharge) or grade 0 (no myotonia) (Figure 14). These 
results are consistent with Clcn1 splicing rescue observed under high heptamidine 
dosages, and show that by correcting DM1 mis-splicing events with a small molecule, 
myotonia symptoms can be alleviated. 
 
 
 
 
Figure 14. Myotonia rescue in HSALR mice treated with 0, 20, or 30 mg/kg heptamidine 
for 7 d. Mice not treated with heptamidine showed myotonic discharge with nearly all 
electrode insertions (grade 3), whereas those treated with 20 or 30 mg/kg heptamidine 
had occasional myotonic discharges with less than 50% of insertions (grade 1) or no 
myotonia (grade 0). 
 
 
In the HSALR mouse model, heptamidine completely reverses Clcn1 mis-splicing and 
partially reverses Atp2a1 mis-splicing at lower concentrations than pentamidine (20). 
Heptamidine also was able to rapidly (one week) and significantly reduce the myotonia 
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phenotype that has been associated with Clcn1 mis-splicing. It is encouraging that 
varying the linker length resulted in significant improvements over our lead compound 
pentamidine, but additional optimization is required. There is still toxicity in both the 
HeLa cell and mouse models (some mice treated with a higher dose of 40 mg kg-1 
heptamidine daily did not survive for one week). We are currently working on analogs 
that will aid in identifying the pharmacophore of pentamidine-like compounds in order to 
guide our design of next generation drugs. 
From our lead compound, pentamidine, we wanted to synthesize analogs that would 
have increased efficacy at disrupting the MBNL1/(CUG)4 complex, lower toxicity, and 
increased cellular permeability. To identify these compounds, we conducted a SAR study 
varying the length of the methylene linker between the phenyl amidines from 3 to 9 
carbons. It seemed likely that increasing the hydrophobic character of the molecule 
would lead to more favorable pharmacodynamic properties by increasing membrane 
permeability. 
In our HeLa cell model of DM1, we observed an increase in efficacy as linker length 
increased (Figure 10-11). However, we are still unsure of the mechanism of pentamidine 
and its analogs in cells and mice. It is possible that these compounds bind the expanded 
CUG repeat RNA and displace MBNL proteins as we originally proposed (20); however, 
due to the BPB complication, and difficulty demonstrating a robust interaction between 
pentamidine and CUG repeat RNA, this mode of action appears increasingly unlikely. 
Alternative models include mechanisms wherein pentamidine does not displace MBNL, 
but rather eliminates the CUG repeats, either through affecting transcription or RNA 
stability. Pentamidine is known to bind double-stranded DNA (65), so it is possible to 
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envision pentamidine interacting with the CTGCAG repeats present in both the HeLa 
cell and mouse models and down-regulating transcription. This would be consistent with 
our previous observation that pentamidine significantly reduced nuclear foci formation in 
HeLa cells (20). However, interactions of pentamidine with CUG repeat RNA that either 
displace MBNL directly or decrease the RNA stability are also consistent with 
observations thus far, and cannot be ruled out. It is also conceivable that pentamidine is 
acting through more than a single mechanism. It is clear that more work needs to be done 
to determine pentamidine’s mode (or modes) of action in order to guide further small 
molecule drug development for DM1. 
METHODS 
MBNL purification. The MBNL1 medium construct (1-260) was purified as 
previously described (20) with the following changes: after purification, the protein was 
dialyzed into 500 mM NaCl, 20 mM Tris pH 7.5, 50% (v/v) glycerol, and 5 mM β-
mercaptoethanol. Aliquots were stored at –80 °C until just before use. 
RNA labeling. The (CUG)4 RNA construct used in the in vitro EMSA (5’-
GCUGCUGUUCGCUGCUG) was ordered from IDT and 5’ end labeled using [γ–
32P]ATP. After phosphorylation, the RNA was purified using a spin column containing 
Bio-Gel P2 Gel (Bio-Rad), brought to final stock concentration of 50 nM using low TE, 
and stored at –20 °C until use. 
Synthesis of pentamidine analogs. Pentamidine isethionate was purchased from 
Sigma-Aldrich and the HCl salt was accessed by recrystallization from hot 10% (w/v) 
aqueous HCl. Propamidine, butamidine and hexamidine were synthesized as described by 
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Tidwell and coworkers (66). Heptamidine, octamidine and nonamidine were prepared in 
an analogous fashion.   
propamidineHCl: White powder. 1H NMR (600 MHz, (CD3)2SO) δ 2.34 (pent, J = 
6.0 Hz, 2H), 4.27 (t, J = 6.0 Hz, 4H), 7.18 (d, J = 9.0 Hz, 4H), 7.86 (d, J = 9.0 Hz, 4H), 
9.08 (br s, 4H), 9.28 (br s, 4H); 13C NMR (150 MHz, (CD3)2SO) δ 28.22, 64.80, 114.80, 
119.52, 130.22, 162.81, 164.67.   
butamidineHCl: White powder. 1H NMR (600 MHz, (CD3)2SO) δ 1.91 (pent, J = 6.0 
Hz, 4H), 4.17 (t, J = 6.0 Hz, 4H), 7.15 (d, J = 9.0 Hz, 4H), 7.88 (d, J =  9.0 Hz, 4H), 9.12 
(br s, 4H), 9.31 (br s, 4H); 13C NMR (150 MHz, (CD3)2SO) δ 25.12, 67.73, 114.77, 
119.31, 130.20, 162.99, 164.70.   
pentamidineHCl: White powder. 1H NMR (600 MHz, (CD3)2SO) δ 1.58 (pent, J = 
7.2 Hz, 2H), 1.80 (pent, J = 6.0, 7.2 Hz, 4H), 4.15 (t, J = 6.0 Hz, 4H), 7.14 (d, J = 9.0 Hz, 
4H), 7.86 (d, J = 9.0 Hz, 4H), 9.11 (br s, 4H), 9.29 (br s, 4H); 13C NMR (150 MHz, 
(CD3)2SO) δ 22.50, 28.60, 68.46, 115.19, 119.69, 130.63, 163.49, 165.14.   
hexamidineHCl: White powder. 1H NMR (600 MHz, (CD3)2SO) δ 1.48 (m, 4H), 
1.76 (pent, J = 6.0 Hz, 4H), 4.09 (t, J = 6.0, 4H), 7.13 (d, J = 9.0 Hz, 4H), 7.87 (d, J = 9.0 
Hz, 4H), 9.11 (br s, 4H), 9.30 (br s, 4H); 13C NMR (150 MHz, (CD3)2SO) δ 25.60, 28.83, 
68.47, 115.18, 119.66, 130.63, 163.49, 165.14.   
heptamidineHCl: White powder. 1H NMR (600 MHz, (CD3)2SO) δ 1.43 (m, 6H), 
1.74 (m, 4H), 4.08 (t, J = 6.6 Hz, 4H), 7.13 (d, J = 8.4 Hz, 4H), 7.88 (d, J =  8.4 Hz, 4H), 
9.14 (br s, 4H), 9.31 (br s, 4H); 13C NMR (150 MHz, (CD3)2SO) δ 25.79, 28.81, 28.87, 
68.50, 115.17, 119.62, 130.63, 163.50, 165.15.   
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octamidineHCl: White powder. 1H NMR (600 MHz, (CD3)2SO) δ 1.35 (m, 4H), 
1.42 (m, 4H), 1.73 (m, 4H), 4.07 (t, J = 6.6 Hz, 4H), 7.13 (d, J = 8.4 Hz, 4H), 7.87 (d, J =  
8.4 Hz, 4H), 9.13 (br s, 4H), 9.31 (br s, 4H); 13C NMR (150 MHz, (CD3)2SO) δ 25.79, 
28.87, 29.10, 68.52, 115.16, 119.62, 130.62, 163.51, 165.15.   
nonamidineHCl: White powder. 1H NMR (600 MHz, (CD3)2SO) δ 1.32 (m, 6H), 
1.40 (m, 4H), 1.73 (m, Hz, 4H), 4.07 (t, J = 6.6 Hz, 4H), 7.13 (d, J = 9.0 Hz, 4H), 7.86 (d, 
J = 9.0 Hz, 4H), 9.09 (br s, 4H), 9.28 (br s, 4H); 13C NMR (150 MHz, (CD3)2SO) δ 
25.83, 28.88, 29.11, 29.36, 68.53, 115.17, 119.65, 130.62, 163.51, 165.14.   
Gel shift assay. The 5’ end labeled (CUG)4 RNA was annealed in 250 mM NaCl, 25 
mM MgCl2, and 75 mM Tris pH 7.5 by heating at 95 °C for 3 min and was cooled on ice 
for 5 min, BSA and heparin were added, and the reaction cooled another 5 min. MBNL1 
was then added to the RNA and incubated at room temperature (RT) for 10 min. 
Pentamidine was added, followed by another 5 min RT incubation, followed by the 
addition of BPB. The final reaction volume of 10 µL was incubated at RT for 25 min. 
Final reaction conditions were 0.5 nM (CUG)4, 175 mM NaCl, 20 mM Tris pH 7.5, 5 
mM MgCl2, 2 mg mL-1 BSA, 0.1 mg mL-1 heparin, 1.25 mM β-mercaptoethanol, 1.25% 
(v/v) glycerol, and 250 nM MBNL1. Then 3 µL of the reaction was run on a 5% (w/v) 
80:1 pre-chilled polyacrylamide gel with 0.5x TB. Gels were run at 4 °C at 170 V for 35 
min, dried, and autoradiographed. IC50 values were calculated as previously described 
(Warf, 2009). In brief, gels were quantified using ImageQuant (Molecular Dynamics). 
The percent of RNA bound was determined by taking the ratio of the RNA:protein  
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complex (including any well shifting) to the total RNA, per lane. IC50 values were 
determined with KaleidaGraph (Synergy) software using the equation 
 
 
 
where m0 = small molecule concentration, m1 = IC50, m2 = Hill coefficient, and m3 = 
fraction of MBNL1 bound without small molecule present. Errors were determined by 
calculating the standard deviation of triplicate data. 
Splicing analysis in cell culture. Splicing was performed as described previously 
(20) with the following changes. Approximately 2 x 105 cells were plated in 6 well plates 
and transfected 24–36 h later. After transfection, cells were incubated in OPTI-mem 
(GIBCO) for 6 h and then washed with 1x PBS and placed in DMEM with GLUTAMAX 
(GIBCO) supplemented with 10% FBS (v/v) (GIBCO) along with pentamidine analogs. 
Cells were harvested after 16–18 h and RNA was isolated immediately using an RNeasy 
kit (QIAGEN). After DNase treatment, RNA was reverse transcribed with SuperScript II 
and a plasmid specific reverse primer. This cDNA was then subjected to PCR (22 rounds 
for INSR or 24 rounds for TNNT2). Resulting PCR products were then run on a 6% (w/v) 
19:1 native polyacrylamide gel containing 0.5x TB at 300 V for 90 min. The gel was then 
stained with 1x SYBR I dye (Applied Biosystems) in 0.5xTB for 15 min. Quantification 
of bands was performed using the Alpha Imager HP software from Alpha Innotech. EC50 
values were determined by performing linear regression analysis of the data using Excel 
(Microsoft), and determining the concentration would result in 50% splicing rescue, 
calculated as halfway between wild type and disease state levels of exon inclusion. 
! 
Y = m3
1+ m0m1( )
m2
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The following primers were used. For the TNNT2 minigene, the RT primer was 5’ 
AGC ATT TAG GTG ACA CTA TAG AAT AGG G. The forward primer for PCR was 
5’ GTT CAC AAC CAT CTA AAG CAA GAT G and the reverse primer was 5’ GTT 
GCA TGG CTG GTG CAG G. For the INSR minigene, the RT primer was 5’ GCT GCA 
ATA AAC AAG TTC TGC. The forward primer for PCR was 5’ CGA ATT CGA ATG 
CTG CTC CTG TCC AAA GAC AG, and the reverse primer was 5’ TCG TGG GCA 
CGC TGG TCG AG. The TNNT2 minigene was a gift from the lab of Thomas Cooper 
and the INSR minigene was a gift from Nicholas Webster. 
Heptamidine treatment of mice. Homozygous HSALR transgenic mice in line 20b 
(FVB inbred background) were previously described (63). Gender-matched mice of 10–
14 wks age were treated with heptamidine at the indicated dose by daily intraperitoneal 
injection for 7 d. Control mice received 5% glucose injections. Mice were sacrificed 1 d 
after the final injection and vastus (quadriceps) muscle was obtained for splicing analysis. 
Mice in the withdrawal (WD) group were treated with 30 mg kg-1 heptamidine for 7 d 
and then left untreated for 10 d before sacrifice. Mice were sacrificed 1 d after final 
treatment and vastus muscle was obtained for splicing analysis. RNA was isolated, 
reverse transcribed, and amplified by PCR, and analyzed on agarose gels using a 
fluorimager as previously described (20). 
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Electromyography. Electromyography was performed under general anesthesia as 
described previously (12). Briefly, at least 10 needle insertions were performed in vastus 
muscle and myotonic discharges were graded on a four point scale: 0, no myotonia; 1, 
occasional myotonic discharge in less than 50% of needle insertions; 2, myotonic 
discharge with more than 50% of insertions; and 3, myotonic discharge with nearly all 
insertions. 
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CHAPTER IV 
UTILIZING THE GAAA TETRALOOP/RECEPTOR TO FACILITATE 
CRYSTAL PACKING AND DETERMINE THE STRUCTURE 
OF A CUG RNA HELIX 
 
I was the primary contributor to the experiments described in the following chapter 
and did all of the writing. Dr. Jeremy Lohman aiding in determining the structure trCUG-
3, and Dr. J. Andrew Berglund was the principal investigator of this work. 
INTRODUCTION 
Microsatellite expansion diseases are the result of aberrant expansion of short 
repeating segments of DNA (between 1–10 bases) (67). These expansions can occur in 
either in coding regions where they result in abnormal proteins (68), or in noncoding 
regions of the genome where upon transcription, act through a toxic RNA gain-of-
function mechanism (40, 69). Myotonic dystrophy (DM), which is the most common 
form of adult onset muscular dystrophy, affecting ~1 in 8000 individuals, is the result of 
microsatellite expansions (reviewed in (40, 59, 67)). DM type 1 (DM1) is caused by a 
CTG expansion in the 3’ untranslated region in the DMPK gene (8). When transcribed to 
RNA, these CUG repeats form stable stem loops, which are capable of sequestering RNA 
binding proteins within nuclear foci (9, 10). One family of sequestered proteins that co-
localizes with expanded CUG repeats, the Muscleblind-like (MBNL) proteins, are 
regulators of alternative splicing, resulting in the mis-splicing of target transcripts, 
leading to disease symptoms (14-18). 
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It is the expanded CUG RNA which is toxic in DM1, and a handful of CUG-repeat 
structures have been published showing that, despite containing a U-U mismatch every 
third base pair, the repeats formed an essentially A-form structure, with the U-U 
mismatches forming only one hydrogen bond without distorting the backbone (33, 35, 
36). However, two of these structures contained some degree of disorder, and all of the 
structures had very tight crystal packing, leaving no potential room for co-crystallization 
with ligands (either small molecules or short peptides). In order to overcome these issues, 
we decided to use an RNA crystallization motif in order to design specific intermolecular 
contacts and minimize close packing, and introduce “free spaces” within the crystal. 
We chose the GAAA tetraloop and its conserved 11-nucleotide receptor as our 
engineered crystal contacts. This tetraloop/receptor was initially identified as a tertiary 
motif in Group I and II self-splicing introns (70-72). The three adenosines in the loop flip 
outward and form specific hydrogen bonds with the 11-nucleotide receptor (72), making 
it an ideal candidate for engineering crystal contacts. This motif has been utilized to aid 
in the crystallization of larger RNA constructs, such as the hepatitis delta virus, among 
others (73, 74). Here, we utilized the tetraloop/receptor to crystallize a short RNA helix 
composed of CUG repeats allowing us to obtain a strongly diffracting crystal. 
Additionally, we were able to use the previously solved structure of the tetraloop/receptor 
as our search model, allowing us to quickly and easily solve the structure using molecular 
replacement. 
MATERIALS and METHODS 
Purification of RNA. RNA was purchased from Dharmacon and desalted per their 
instructions. RNA was then resuspended in 1x denaturing dye (25% w/w formamide, 1x 
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TBE, 0.1% bromophenol blue, 0.1% xylene cyanol) and run on a denaturing 
8% polyacrylamide (19:1) gel with 7 M urea. RNA was located using UV shadowing, 
excised and eluted overnight using the Elutrap Electroelution System (Whatman) in 1x 
TBE. RNA was then ethanol precipitated and resuspended in ddH2O and desalted using a 
Micro Bio-Spin column with Bio-Gel P2 Gel (Bio-Rad). RNA was brought to a final 
concentration of 0.5 mM in a solution of 15 mM NaCl, 5 mM Tris pH 7.5, and 
5 mM MgCl2. 
RNA crystallization. The RNAs were annealed by heating to 70 ºC for 5 min and 
rapidly cooled to 4 ºC. RNAs were screened for crystallization using the Mosquito nano-
liter high throughput robot (TTP labtech) and the Natrix screen (Hampton Research) by 
the hanging drop vapor diffusion method at room temperature. Promising hits were 
screened in 4 µL hanging drops. The best crystals of trCUG-3 were grown from a 
mixture of 2 µL RNA solution and 2 µL well solution containing 4 mM MgSO4, 50 mM 
Tris pH 8.5, and 30% (w/v) 1,6-hexanediol. Crystals appeared in approximately 
one week. 
Data collection. Crystals of at least 0.02 mm in the smallest dimension were mounted 
in rayon loops and flash frozen in liquid nitrogen. Experimental data were collected at 
Advanced Light Source BL 5.0.1 under a cryostream. The x-ray data were integrated, 
merged, and scaled using the HKL-2000 program suite (75), and converted to structure 
factors using the CCP4i GUI (76) for the CCP4 program suite (77). Data collection 
statistics are listed in Table 2. 
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Table 2. Summary of data collection and refinement statistics 
Measurement Value 
Spacegroup R3 
Unit cell dimensions    a, b, c (Å) 70.34 70.34 68.24 
α, β, γ (°) 90 90 120 
Resolution range, Å 22.75 – 1.95 
Total number of reflections 98787 
Number of unique reflections 8621 
Average redundancy 5.5 
% completeness 99.3 (98.9) 
I/σI 37.0 (2.2) 
Rmerge a 0.068 (0.60) 
Average B-factors [atoms]  
 nucleotides 54.58 [744] 
 solvent 60.53 [44] 
Rfree b 0.266 
Rwork b 0.208 
 
 
 
 
 
 
 
 
 
Values in parentheses represent highest resolution shell 
 
a !!"#$" = |!!!!!|!!!  where I is the observed intensity and <I> is the average of intensities 
obtained from multiple observations of symmetry-related reflections. 
 
b !!"#$%& = ||!!|!|!!|||!!|  where Fo and Fc are the observed and calculated structure 
amplitudes, respectively. 
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Structure determination. Structure was solved using the molecular replacement 
method by the program molrep (78), a part of the CCP4 program suite (77), with the 
tetraloop/receptor from 1GID, the structure of group I ribozyme domain (72), as the 
search model. The model was manually rebuilt using Coot (79), and refined using refmac 
(80). Coot and PyMOL (81) were used to generate figures. Refinement statistics are listed 
in Table 2. Structural parameters were calculated using 3DNA (82). 
RESULTS 
Design of RNA constructs for crystallization. In order to overcome crystallographic 
disorder present in previous CUG repeat structures (33, 35), we designed ten different 
constructs utilizing the GAAA tetraloop/receptor to facilitate intermolecular contacts 
(Figure 15). Each construct contained either four or six CUG repeats, one or two 
stabilizing base pairs, the receptor, a short upper helix, and the GAAA tetraloop. The 
upper helix was kept short in order to favor intermolecular rather than intramolecular 
interactions. Only trCUG-8 failed to form any crystals, possibly due to the 3’ 
overhanging nucleotide. Of the remaining constructs, only trCUG-2, 3, 6, and 10 grew 
crystals of sufficient size to mount. Neither trCUG-2 nor trCUG-10 diffracted to better 
than 10Å. Both trCUG-3 and trCUG-6 diffracted to better than 3Å resolution; however, 
the 3’ overhanging G of trCUG-6 was disordered, and both structures looked essentially 
the same. 
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Figure 15. Sequence of RNAs used to identify CUG repeat containing crystals that 
diffracted to high resolution using the tetraloop/receptor crystallization module. Each 
RNA construct consists of four or six CUG repeats (highlighted in blue), the 11-
nucleotide receptor, a short upper stem, and the GAAA tetraloop. Below each 
sequence is a representative picture of how well each RNA crystallized. The only 
sizable trCUG-6 crystal grew off a fiber. 
 
 
Structure determination using tetraloop/receptor as a model for molecular 
replacement. Since the sequence, and presumably the structure, of the tetraloop/receptor 
in trCUG-3 was the same as the tetraloop/receptor in the group I ribozyme domain 
structure determined by Cate et al. (72) (with the exception of the first base pair, which 
was reversed), this portion of their structure was used for molecular replacement. The 
11-nucleotide receptor and the 4-nucleotide loop (plus the two adjacent base pairs) was 
successfully used as our search model. The un-modeled base pairs were clearly visible in 
the maps and the nucleotides were easily modeled into the density (Figure 16A).  
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Figure 16. Structure and crystal packing of trCUG-3. (A) Molecular replacement 
solution and 2Fo-Fc map (contoured at 1.5 σ) after one round of refinement. The 
density of the base pairs not yet modeled, both between the tetraloop/receptor and 
directly below the receptor, are clearly observable in the density (red arrows). (B) 
Secondary structure of trCUG-3. The (CUG)2 region, containing four CUG repeats at 
the base of the hairpin, is denoted by a bracket. Magnesium ions are represented by 
numbered gray spheres. Waters not shown. (C) Crystal packing of trCUG-3. Each 
RNA interacts with four other RNAs in the structure: at the loop, at the receptor, on 
the opposite side of the receptor and at the bottom of the helix. Tetraloop and receptor 
are denoted by lighter colors. Inset gives a closer view of each interaction. 
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Five peaks were observed in the maps that were unlikely to be waters due to geometric 
considerations, and based on previous structures of the tetraloop/receptor (72, 83, 84) and 
their proximity to the phosphate backbone, we modeled the peaks as magnesium ions 
(Figure 16B). The final model has 35 nucleotides, 44 water molecules, and five 
magnesium ions with an Rwork and Rfree of 0.208 and 0.266, respectively. 
Structure of trCUG-3. The 35-nucleotide trCUG-3 RNA crystallized in space group 
R3. As designed, the RNA formed a hairpin with a GAAA tetraloop, a short five base 
pair stem, the tetraloop/receptor, and an eight base pair CUG-containing stem (Figure 
16B). The upper stem begins and ends with a GU wobble base pair. The lower stem 
contains two different U-U mismatches, while the G-C base pairs formed Watson-Crick 
interactions. Each RNA makes specific crystal contacts with four other RNAs: two of 
these interactions were predicted tetraloop/receptor interactions, and two were the 
unanticipated stacking of the base of the helix against the opposite side of the receptor of 
a symmetry mate (Figure 16C). 
 
 
Figure 17 (next page). Comparison of U-U mismatches in the context of CUG repeats. 
(A) Lower and upper U-U mismatch of trCUG-3. The upper U5-U31 mismatch forms 
the more typical (in the context of CUG repeats) one hydrogen bond, while the lower 
U2-U34 mismatch forms two hydrogen bonds, shortening the C1’-C1’ distance. (B) 
U-U mismatches of the de-twinned (CUG)6 structure. All U-U mismatches in this 
structure form one hydrogen bond, maintaining the C1’-C1’ distance typical of a 
Watson-Crick interaction. (C) U-U mismatches from the NMR structure of 
CCGCUGCGG, forming zero, one, or two hydrogen bonds. (D) U-U mismatches 
from G(CUG)2C crystal structure. The first column contains the U-U mismatches in 
duplex A+B, the second contains C+D and the third contains E+E*. Every mismatch 
within the G(CUG)2C crystal structure forms one hydrogen bond. (E-F) U-U 
mismatches from UUGGGC(CUG)3CUCC pdb entry 3SYW (E) and 3SZX (F). 
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Within the CUG-containing stem, two different conformations of the U-U mismatch 
were observed (Figure 17A). The lower U2-U34 mismatch formed two hydrogen bonds, 
which resulted in a shorter C1’-C1’ distance (8.6 Å) as compared to the upper U5-U31 
mismatch, which formed one hydrogen bond and had a C1’-C1’ distance of 10.6 Å 
(Table 3). Both mismatches were inclined towards the minor groove (λ1 < 54°), and as a 
result, do not appear to stack with the preceding C. The incline was more severe in the 
U5-U31 mismatch, which is most likely a result of the single hydrogen bond. 
Examining the overall structure of the CUG portion of the lower helix (hereafter referred 
to as (CUG)2) reveals that it is primarily an A-form helix. The average helical rise of 
(CUG)2 is 2.39 Å (Table 4), which is closer to an A-form conformation (2.83 Å) than a 
B-form conformation (3.29 Å) (85). The average helical twist is 35.9°, which is greater 
than the expected 32.5° for A-form, and not much less than the expected 36.5° for B-
form. Base pairs in (CUG)2 are also steeply inclined (18.6°) as is expected for A-form 
helices. Local dimer step parameters, including roll, twist, slide, and most importantly zP 
and zP(h), also match well with average A-form values (Table 4). Interestingly, the 
structure did not seem to be affected, beyond the first CU/UG step, by the crystal packing 
interaction that occurred at the base of the helix (Figure 16C). This base pair step was 
strongly tipped (20.6°), tilted (-11.3°), and rolled (19.4°) as compared to the other base 
pairs in the structure. 
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Table 3. Comparison of U-U mismatches 
 
 
 
C1'-
C1' 
(Å) 
1st 
hbond 
(Å) 
2nd 
hbond 
(Å) 
λ I 
(°) 
λ II 
(°) Incline
1 Shear 
(°) 
Stretch 
(Å) 
Stagger 
(Å) 
Buckle 
(°) 
Propeller 
(Å) 
Opening 
(°) Type 
trCUG-3 U2-U34 8.6 2.8 2.8 44.8 75.9 minor -2.47 -1.89 0.26 -7.12 -16.4 11.6 Type I U5-U31 10.6 2.7 - 28.2 55.8 minor -2.63 -1.33 -0.1 5.62 -7.12 -25.98 Type II 
(CUG)6 
(35) 
U2-U17 10.3 2.7 - 34.1 56.7 minor -2.32 -1.38 -0.18 0.89 -9.98 -21.23 Type II 
U5-U14 10.6 3 - 53.8 33.1 major 2.27 -1.17 -0.36 -6.03 -15.03 -22.06 Type IV 
U-8-U11 10.3 2.7 - 32.4 56.9 minor -2.5 -1.48 0.45 2.36 -11.27 -21.02 Type II 
U11-U8 10 2.9 - 57.8 40.4 major 1.71 -1.29 -0.44 -1.86 -12.2 -11.93 Type IV 
U14-U5 10.5 2.7 - 55.9 32.4 major 2.65 -1.29 -0.23 6.92 -11.44 -28.01 Type IV 
U17-U2 10.3 3 - 58.2 39.2 major 2.04 -1.11 -0.15 -4.69 -14.81 -14.8 Type IV 
Disney 
NMR 
(37) 
U5-U14 (0) 10.7 - - 71.2 32 major 3.57 -0.95 -0.05 -13.48 -9.09 -5.62 Type VI 
U5-U14 (1) 10.6 2.9 - 61.1 28.9 major 3.03 -1.14 -0.09 -22.07 -6.46 -24.3 Type IV 
U5-U14 (2) 8.9 2.9 2.9 73.3 48.3 major 2.24 -1.74 0.02 12.56 -17.25 4.58 Type V 
Kiliszek 
A-B (35) 
U3-U6 10.7 2.8 - 26.2 57.9 minor -2.82 -1.19 -0.47 12.51 -8.17 -31.5 Type II 
U6-U3 10.3 2.9 - 31.6 67.7 minor -3.03 -1.31 -0.13 14.01 -8.36 -16.37 Type II 
Kiliszek 
C-D (35) 
U3-U6 10.9 2.8 - 56.1 22.6 major 2.98 -1.22 -0.44 -4.51 -8.69 -34.42 Type IV 
U6-U3 10.2 2.6 - 59.2 32.4 major 2.59 -1.51 -0.28 0.57 -15.81 -21.16 Type IV 
Kiliszek 
E-E* (35) 
U3-U6 10.6 2.6 - 52.7 29.1 major 2.38 -1.31 -0.48 -4.07 -11.84 -30.56 Type IV 
U6-U3 10.6 2.6 - 29.1 52.7 minor -2.38 -1.31 -0.48 4.07 -11.84 -30.56 Type II 
Disney 
3SYW 
(36) 
U8-U14 8.8 3 3 46.3 72.4 minor -2.2 -1.7 0.21 0.27 -14.34 10.06 Type I 
U11-U11 9.9 - - 50.8 50.8 none 0.01 -1.17 0.07 0.11 -5.73 -8.25 Type III 
U14-U8 8.8 2.9 3 72.5 46.3 major 2.2 -1.71 0.21 -0.76 -14.31 10 Type V 
Disney 
3SZX 
(36) 
U8-U14 10.5 2.7 - 53.9 35.3 major 1.85 -1.16 -0.11 -5.24 -8.68 -29.19 Type IV 
U11-U11 10 - - 46 53 none 0.14 -0.99 0.18 1.98 -10.74 -0.21 Type III 
U14-U8 10.5 - - 58.8 48.1 major 1.3 -0.7 -0.3 -2.99 -11.12 -8.97 Type VI 
 
 
Classification # of hbonds Incline Amount 
Type I 2 minor 2 
Type II 1 minor 6 
Type III 0 none 2 
Type IV 1 major 9 
Type V 2 major 2 
Type VI 0 major 2 
 
 
 
 
 
1Direction of incline was determined by considering the 
difference between λI and λII. If (λI – λII) < -8, then the 
pair was considered to be inclined toward the minor 
groove; however, if the difference was > 8, the pair was 
considered to be inclined toward the major groove. Any 
values between -8 and 8 were considered to be not inclined. 
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Table 4. Comparison of CUG repeat helical parameters 
 
 Roll Twist Slide Rise Inclination Helical twist x-displacement Helical rise Zp Zp(h) 
B Form1 0.60 36.00 0.23 3.32 2.10 36.50 0.05 3.29 -0.36 -0.02 
A Form1 8.00 31.10 -1.53 3.31 14.70 32.50 -4.17 2.83 2.24 4.19 
(CUG)2 9.17 33.48 -1.34 3.10 18.57 35.89 -4.70 2.39 2.35 4.62 
(CUG)6 9.16 32.77 -1.90 3.25 16.98 34.54 -5.08 2.49 2.69 4.81 
A-B 6.55 31.70 -1.80 3.32 12.41 33.25 -4.55 2.96 2.52 4.10 
C-D 8.56 33.11 -1.59 3.30 6.93 34.78 -4.58 2.66 2.40 4.57 
E-E* 6.78 32.77 -1.90 3.32 14.12 34.05 -5.03 2.69 2.52 4.32 
3SYW 8.51 28.68 -1.73 3.16 18.76 30.62 -5.27 2.39 2.27 4.64 
3SZX 8.63 32.33 -1.64 3.21 14.93 33.55 -4.26 2.71 2.52 4.46 
 
1A and B-form structural parameters from reference (82) 
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Within the structure, we identified five suspected magnesium ions. Two were near the 
GAAA tetraloop, two more flanked the 11-nucleotide receptor, and the final magnesium 
ion was near the center of the CUG portion of the lower helix (Figure 16B). Only the 
third and fourth magnesium ions were close enough to the RNA to be making direct 
contacts: the rest were making interactions via water molecules. Although none of the 
suspected magnesium ions appeared to be fully coordinated, the first and second 
magnesium ions near the loop interacted with four water molecules. 
DISCUSSION 
Comparison to other CUG helices. To date, there have been four other crystal 
structures of CUG repeat RNA crystal structures published (33, 35, 36). The first, and 
longest, to be crystallized was a (CUG)6 duplex (33). Unfortunately, this construct 
crystallized with twofold translational disorder, complicating analysis. The next structure 
to be released was another duplex: G(CUG)2C (35). This structure contained three 
different duplexes within the same unit cell: the A+B duplex, the C+D duplex, and the 
E+E* duplex, which were related to one another by crystallographic symmetry. This 
publication also de-twinned the data from Mooers et al. The final two structures are 
different conformations of a third duplex: UUGGGC(CUG)3UCC (36). Using 3DNA, we 
compared the helical parameters of (CUG)2 to the (5’CUG/3’GUC)x portions of these six 
structures. (For simplicity, the de-twinned (CUG)6 data were used.) 
Overall, all seven structures appeared to be more similar to an A-form helix than a B-
form helix, especially when parameters that demonstrate the greatest distinction between 
A-form and B-form are considered (roll, slide, inclination, x-displacement, zP, and zP(h)) 
(Table 4). Although (CUG)2 from trCUG-3 has the greatest helical twist of all the 
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published CUG helices (35.9°), it also has the smallest helical rise (2.39 Å). In general, it 
appears that the (CUG)2 model is consistent with existing models. 
U-U mismatches are dynamic. In addition to comparing helical parameters of other 
CUG structures, we also examined all the U-U mismatches, in the context of CUG 
repeats that were available (Figure 17, Table 3). U-U mismatches from all the CUG 
crystal structures (33, 35, 36) and an NMR structure (37) were compared. By examining 
these mismatches, it is clear that the U-U mismatch in the 5’CUG/3’GUC motif is 
dynamic, and at least six unique conformations have been captured, considering just 
potential number of hydrogen bonds and direction of inclination (towards the major or 
minor groove, or not inclined). There is one other potential type of U-U mismatch that 
has not been observed in the currently available data, which is a mismatch with no 
hydrogen bonds inclined towards the minor groove. It is likely this type of mismatch 
occurs (as a counterpart to type VI, which also forms no hydrogen bonds, but is inclined 
toward the major groove) and has simply not been observed/reported at this time. 
Within the trCUG-3 structure, we find two of the six types: type I and II (Figure 17A, 
Table 3). The type I mismatch forms two hydrogen bonds, shortening the C1’-C1’ 
distance, and is inclined towards the minor groove. One other type I mismatch has been 
observed, in UUGGGC(CUG)3UCC (Figure 17E) (36), suggesting this is an actual 
conformation and not simply due to potential distortion of the helix of (CUG)2 due to the 
crystal packing at the base of the trCUG-3 helix. The other mismatch we observed was a 
type II mismatch, the second most frequent type of U-U mismatch. The type II mismatch 
is also inclined towards the minor groove but forms only one hydrogen bond. It is 
observed twice in (CUG)6 (Figure 17B), twice in the G(CUG)2C A+B duplex, and once in 
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the E+E* duplex (Figure 17D). The most commonly observed mismatch, type IV, is the 
counterpart to type II, and forms one hydrogen bond while being inclined toward the 
major groove. It is found four times in (CUG)6 (Figure 17B), in the NMR structures 
(Figure 17C), twice in the G(CUG)2C C+D duplex, once in the E+E* duplex (Figure 
17D), and once in the UUGGGC(CUG)3UCC duplex (Figure 17F). Of course, in 
solution, it is probable that the U-U mismatches found in the 5’CUG/3’GUC motif 
sample all these conformations, and that these “types” of U-U mismatches are not 
discrete, but rather found in a continuum of different states. These data are consistent 
with the flexibility observed in the NMR structure of the CCGCUGCGG duplex 
(Figure 17C) (37). 
Metal ions in structure. Within the trCUG-3 crystal structure, we identified five 
potential magnesium ions. It is unsurprising that magnesium ions would be identified 
within the structure, especially the tetraloop/receptor region, since it has previously been 
shown that tetraloop/receptor interaction is dependent on magnesium (86) or other 
divalent metal ions (87). Several other structures of the GAAA tetraloop/receptor have 
been published, so we compared our structure and metal ion sites with several previously 
published structures (Figure 18). Comparing trCUG-3 and 1GID (72), we observe our 
first three magnesium ions surrounding the cobalt hexamine ion found near the GAAA 
loop (Figure 18B). Our fourth magnesium ion near the receptor has a nearby counterpart 
in 1GID. When compared to 1HR2 (83) (Figure 18C), we see a very similar picture: our 
first three magnesium ions surround one magnesium ion near the loop. However, the 
second, third, and fourth magnesium ions all have nearby counterparts in the 1HR2 
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Figure 18. Alignment of trCUG-3 with two different GAAA tetraloop/receptor 
structures. (A) Structure of trCUG-3 and a symmetry mate used for comparison to 
other tetraloop/receptor structures. Magnesium ions are numbered. (B) Alignment of 
the tetraloop/receptor of trCUG-3 (blue) with that of 1GID (orange). The first three 
magnesium ions surround the cobalt hexamine ion found in 1GID. The fourth 
magnesium ion near the receptor is near a corresponding magnesium ion in 1GID. (C) 
Alignment of the tetraloop/receptor of trCUG-3 (blue) with that of 1HR2 (orange). 
Again, the first three magnesium ions in trCUG-3 surround a single magnesium ion 
found in 1HR2. The second, third and fourth magnesium ions also have counterparts 
near the receptor. 
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structure. The additional ions observed in our structure may be due to the close proximity 
of our tetraloop and receptor as compared to either 1GID or 1HR2, or it could simply be 
that the magnesium ions are not important for making specific contacts with the RNA, 
but rather important for allowing close contact between RNA strands. 
It is clear that utilizing the GAAA tetraloop/receptor was a successful strategy for 
crystallizing a short helix and avoids the pseudosymmetry problems associated with 
duplex RNA. Additionally, examining the crystal packing of this particular construct, we 
observe a large “open” space in the crystal lattice (Figure 19), which could potentially 
allow co-crystallization of small molecules, short peptoids, and possibly small zinc-finger 
domains in complex with the CUG stem. This GAAA tetraloop/receptor framework can 
also be utilized to crystallize other short repeat RNA stems, such as the CCUG repeats 
responsible for DM2 (11), CAG repeats responsible for many spinocerebellar ataxias, and 
CGG repeats responsible for fragile X-associated tremor ataxia syndrome, among many 
others (reviewed in (88)). We have already crystallized a CCUG helix utilizing the 
tetraloop/receptor construct, which diffracted to a resolution of better than 3 Å 
(data not shown). 
We have crystallized a CUG containing RNA construct that has captured two 
different orientations of the clearly mobile U-U mismatch. By examining other crystal 
and NMR structures, it is clear that U-U mismatches, in the context of CUG repeats, can 
flex between many different conformations, from fully paired with one another, to only 
sharing a single hydrogen bond, to being too distant to interact with one another 
(Figure 3). Additionally, these U-U mismatches can go from being inclined towards the 
  
 58 
 
 
 
Figure 19. Structure and 2Fo-Fc map contoured at 1.5 σ near the CUG repeat stem. 
Yellow area highlights large open space near the minor groove of the (CUG)2 stem. 
 
 
 
minor groove, through no inclination, all the way to being inclined towards the major 
groove. This conformational heterogeneity suggests a weak interaction that may play an 
important role in MBNL proteins gaining access to single stranded CUG repeats in order 
to bind the Watson-Crick face of the GC dinucleotide as found in the MBNL-RNA 
crystal structure (3D2S) (39). 
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CHAPTER V 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Pentamidine requires the dye bromophenol blue (BPB) for efficient disruption of 
the MBNL1/(CUG)4 complex in vitro 
The initial small scale screen for molecules that could disrupt the MBNL1/(CUG)4 
complex was performed using BPB, a dye use to monitor reaction mixtures and progress 
through the polyacrylamide matrix. What we did not realize during these experiments 
was that BPB itself was able to compete with the complex with an IC50 of approximately 
1 mM (Chapter II, Figure 5). When I tested the ability of pentamidine to disrupt the 
MBNL1/(CUG)4 complex in the absence of BPB, I was not able to observe any 
competition in the concentration range in which pentamidine and the RNA remained 
soluble. However, when pentamidine and BPB are used in combination, they function in 
a synergistic manner (Chapter II, Figure 6). I found that at least 200 µM BPB was 
required to observe competition under the conditions used for the EMSA. 
I was also interested if other phenolsulphonphthalein dyes would be able to function 
similarly to BPB in disrupting the MBNL1/(CUG)4 complex alone and in conjunction 
with pentamidine. Of the six dyes tested, only BPB and IPB were able to disrupt the 
complex on their own. In combination with 50 µM pentamidine, CPB, BPB, and IPB all 
showed increased efficacy (Chapter II, Figure 7). Overall, it appeared that the activity of 
the phenolsulphonphthalein dyes was greatly affected by the halogenation, and that the 
more electronegative the halogen, the less effective the complex disruption. 
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We suspect that the phenolsulphonphthalein dyes disrupt the protein/RNA complex 
through interactions with MBNL1 rather than (CUG)4 since BPB and other 
phenolsulphonphthalein dyes are known to interact with other proteins (48-51, 58, 89). 
Indeed, we may be able to reduce the necessary concentration of BPB required to observe 
efficient MBNL1/(CUG)4 complex disruption by reducing the amount of BSA present in 
the reaction, which would effectively raise the concentration of “free” BPB. It is clear 
that pentamidine’s mechanism of action is not as simple as we first predicted, since 
pentamidine requires BPB efficiently disrupt the MBNL1/(CUG)4 complex. Additionally, 
something else must be occurring in cells, since no BPB is added to the HeLa cell assay, 
and yet pentamidine is able to reverse mis-splicing events. We decided to further 
investigate pentamidine’s mode of action in the DM1 HeLa cell model. 
Pentamidine reduces the amount of (CUG)960 transcript within DM1 HeLa model 
Due to the BPB complications with the competitive EMSA, and our inability to 
measure a high affinity interaction between CUG repeats and pentamidine, we began to 
question if pentamidine was acting via a mechanism other than (or in addition to) direct 
binding to extended CUG repeats, displacing MBNL. In order to examine other potential 
mechanisms through which pentamidine could act, I decided to observe (CUG)960 levels 
with and without pentamidine treatment (Figure 20). Pentamidine clearly reduces CUG 
repeat transcript levels while not affecting GAPDH levels. This suggests that pentamidine 
is acting specifically on the transfected DNA or its transcript, rather than generally 
affecting transcription. In order to further examine pentamidine’s effect on transcript 
levels, we are planning to perform an RNA-seq experiment, using both a HeLa cell DM1 
model as well as myoblasts from DM1 patients treated with several different 
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concentrations of pentamidine. Through this transcriptional profiling, we will not only be 
able to observe changes in transcript levels, but also changes in alternative splicing, 
alternative promoter usage, and alternative polyadenylation sites. 
 
 
 
 
Figure 20. Northern of (CUG)960 levels. The first lane is mock transfected HeLa cells 
which are not expressing CUG repeats. In the cells expressing 960 CUG repeats, 
levels of CUG transcripts drop as cells are treated with increasing concentrations of 
pentamidine (0, 20, 40, and 60 µM) while GAPDH levels remain the same. 
 
 
 
These data suggest that pentamidine can act through some other mechanism, either 
instead of or in addition to, binding to CUG repeat RNA and displacing MBNL. Exactly 
what that mechanism is we have not yet determined. Pentamidine could be binding to 
CTG repeat DNA and inhibiting transcription, it could be affecting stability of the CUG 
repeats, it could be interacting with a DNA/RNA hybrid, or some combination of 
mechanisms of action. More work needs to be done in order to elucidate pentamidine’s 
mode of action in vivo. We also want to determine if pentamidine can reduce CUG 
transcripts in patient myoblasts as well as in the DM1 mouse model. 
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As methylene linker length increases, pentamidine analogs become more effective 
Due to the BPB complications with the competitive EMSA, and the fact that 
pentamidine reduces (CUG)960 transcript levels, we decided to screen our compounds 
using the HeLa cell splicing rescue assay (competitive EMSA characterization can be 
found in Appendix A). We observed that analogs with longer methylene linker lengths 
had better efficacy than those with shorter linkers (Chapter III, Figure 10-12). 
Interestingly, these results correlate with the EMSA characterizations: as linker length 
increased, analogs were better at disrupting the MBNL1/(CUG)4 complex. There are 
several possible reasons for the correlation. It is possible the correlation is simply 
coincidental: longer linkers may bind (CUG)4 with higher affinity, while longer linkers 
are more hydrophobic, leading to better ability to cross the cellular membrane, effectively 
raising the intracellular concentration. There is also a possibility that while optimizing the 
compounds for (CUG)4, we also accidentally optimized them for CTG repeat DNA, 
leading to better inhibition of transcription. On the other hand, it may be that pentamidine 
and its analogs do bind to the CUG repeat RNA and trigger its degradation, so 
optimization in the EMSA would be observed as better efficacy in the splicing assay. 
Finally, we have not ruled out that pentamidine is able to bind to expanded CUG repeats 
in the cell and displace MBNL as was originally hypothesized (20) or that there could be 
a combination of these different modes of action happening simultaneously. 
After screening seven pentamidine analogs, we tested our best compound that 
remained water soluble (heptamidine) in a mouse model of DM1. We observed that 
heptamidine was able to completely reverse the mis-splicing of the Clcn1 gene and 
partially rescue the Apt2a1 gene in a dose dependent manner. After seven days of 
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treatment, mice that went untreated for an additional ten days showed a complete 
reversion to disease levels of splicing, demonstrating that heptamidine treatment was 
responsible for the change. Additionally, mice that were treated with the highest doses of 
heptamidine saw significant reduction in the myotonia phenotype. This demonstrates that 
we can make chemical modifications to our lead drug compounds to identify other 
potential small molecules that may be more effective and/or less toxic than pentamidine. 
It also demonstrates that a small molecule can be successful, not only at reversing DM 
related mis-splicing, but also at alleviating symptoms as well. However, we still need to 
identify pentamidine’s mode of action in order to better guide our future drug design. 
Crystallization of a CUG repeat stem by utilizing a crystallization motif 
If pentamidine or other small molecule drug targets are interacting with CUG repeat 
RNA, it would be helpful to crystallize the two together, in order to design molecules 
with higher affinity and specificity. The currently crystallized constructs contained either 
disorder (33) or were packed too tightly to allow for co-crystallization with a small 
molecule (35, 36). We successfully overcame both these issues by utilizing the GAAA 
tetraloop/receptor attached to a CUG repeat stem to engineer crystal contacts. The 
tetraloop/receptor locked the stem into a specific orientation, eliminating disorder, while 
also leaving free space along the side of the helix, which could allow for co-
crystallization with small molecules or short peptides. 
I also compared the trCUG-3 structure with all other available CUG repeat structures 
and found that although all the structures appear to be essentially A-form, that the U-U 
mismatches have a wide range of conformations (Chapter IV, Figure 17, Table 3). I 
identified six different types of U-U mismatches in the context of the 5’CUG/3’GUC 
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motif based on direction of inclination and number of hydrogen bonds formed (Chapter 
IV, Figure 17, Table 3). I also predict a seventh type of U-U mismatch that has not yet 
been reported. I have also used this GAAA tetraloop/receptor motif to facilitate the 
crystallization of other short duplex RNAs including the CCUG repeats of DM2. It will 
be interesting to see if the C-U mismatches are similarly dynamic. 
  
 65 
 
APPENDIX 
CHARACTERIZATION OF PENTAMIDINE METHYLENE LINKER 
ANALOGS USING COMPETITIVE EMSA 
 
Introduction 
In addition to the in vivo splicing assay used to characterize pentamidine analogs 
discussed in Chapter III, all seven analogs were also characterized with the competitive 
EMSA, which was used in the small scale screen that discovered pentamidine as a 
potential drug candidate for DM1. Due to the requirement of BPB in order to observe 
efficient MBNL1/(CUG)4 complex disruption (discussed in Chapter II), and because 
pentamidine reduced (CUG)960 transcript levels (discussed in Chapter V), these results 
were not included in the manuscript that composes Chapter III. 
In an effort to develop a pentamidine analog with improved physiochemical 
properties, we undertook a structure activity relationship (SAR) study. Analogs 
containing three to nine methylene carbons were synthesized and tested using the in vitro 
EMSA assay for their ability to compete with the MBNL1/(CUG)4 complex, and in vivo 
for their ability to rescue the mis-splicing of MBNL regulated minigenes in the HeLa cell 
splicing assay (discussed in Chapter IV). In general, analogs containing more methylenes 
had lower IC50 values in the EMSA and more efficiently rescued splicing. The most 
promising compound, heptamidine, was tested for its ability to rescue mis-splicing and 
myotonia in a transgenic mouse model of DM1. 
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RESULTS 
In vitro efficacy increases with linker length 
A common tactic to improve the physiochemical properties of a drug candidate is to 
vary the hydrophobicity of the molecule, and we utilized this strategy by varying the 
length of pentamidine’s methylene linker. The most polar analog being propamidine, 
with a three carbon linker, and the least polar being nonamidine, with a linker of nine 
carbons (Figure 21a). The activities of these compounds were tested using the 
competitive EMSA in which MBNL1 and (CUG)4 (a small hairpin RNA composed of 
two CUG repeats, a UUCG cap, and two more CUG repeats) were held constant. As 
molecules were added, those effective at disrupting the MBNL1/(CUG)4 complex caused 
an increase in free RNA. We found that propamidine had the lowest activity, with an IC50 
of 250 ± 10 µM, followed by butamidine (IC50 = 85 ± 17 µM), both of which disrupted 
complexes less effectively than our lead compound pentamidine (IC50 = 39 ± 2 µM) 
(Figure 21b,c Table 5). Analogs with longer linkers showed an improvement over 
pentamidine. Hexamidine disrupted the MBNL1/(CUG)4 complex with an IC50 of 26 ± 2 
µM. Heptamidine and octamidine were comparable with IC50 values of 20 ± 2 µM and 20 
± 1 µM, respectively. Nonamidine was the most effective in our competitive EMSA with 
an IC50 of 14 ± 1 µM (Figure 21b,c, Table 5). These results showed that analogs 
containing longer oligomethylene linkers are more effective at disrupting the 
MBNL1/(CUG)4 complex. 
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Figure 21. Pentamidine analogs containing longer linkers disrupt the MBNL1/(CUG)4 
complex more effectively. (a) Structure of the pentamidine analogs. Methylene 
carbon linker highlighted by gray parenthesis. (b) EMSA of the competition with the 
MBNL1/(CUG)4 complex. Each compound can compete with the MBNL1/(CUG)4 
complex. (c) IC50 curves for each linker analog. Left graph shows propamidine, 
butamidine, and pentamidine on a scale from 0–450 µM, and the right graph shows 
pentamidine, hexamidine, heptamidine, octamidine, and nonamidine on a scale from 
0–50 µM since they are more effective. Error bars are standard deviation for each 
point. 
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Table 5. Structures and IC50 of each linker analog. 
Small molecule Name Linker length IC50 
 
propamidine 3 250 ± 10 µM 
 
butamidine 4 85 ± 17 µM 
 
pentamidine 5 39 ± 2 µM 
 
hexamidine 6 26 ± 2 µM 
 
heptamidine 7 20 ± 2 µM 
 
octamidine 8 20 ± 1 µM 
 
nonamidine 9 14 ± 1 µM 
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DISCUSSION 
From our lead compound, pentamidine, we wanted to synthesize analogs that would 
have increased efficacy at disrupting the MBNL1/(CUG)4 complex, lower toxicity, and 
increased ability to be absorbed by cells (further discussed in Chapter III). To identify 
these compounds, we conducted a SAR study varying the length of the methylene linker 
between the phenyl amidines from 3 to 9 carbons. We suspected that by varying the chain 
length, we could fine-tune the distance between the positively charged amidine groups on 
either side of the molecule. We hypothesize that pentamidine binds the stretched U-U 
wobble pairs present in the CUG helix (33, 35) because bulges are often sites of small 
molecule/RNA interactions. We suspected varying the number of methylenes would 
either allow the charged amidines to adopt a more favorable conformation for hydrogen 
bonding or strengthen hydrophobic interactions between the molecule and RNA (a key 
component of pentamidine’s selective interaction with A/T rich DNA (65)). Finally, it 
seemed likely that increasing the hydrophobic character of the molecule would lead to 
more favorable pharmacodynamic properties by increasing membrane permeability. 
In our competitive EMSA, we observed an increase in efficacy as linker length 
increased (Figure 22). However, since we did not identify an optimal linker length, we 
cannot be sure that the observed increase in efficacy was strictly due to an ideal distance 
between the amidine ends of the molecules. It is possible that the hydrophobic linker 
contributes significantly to the analog’s activity. 
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Figure 22. Plot of IC50 values versus methylene linker length. As length increases, IC50 
decreases. Error bars are standard deviation. 
 
METHODS 
Protein purification, RNA labeling, analog synthesis, and competitive EMSA were 
conducted as described in Chapter III. 
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